Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?

Author(s): Konstantinos Imprialos, Konstantinos Koutsampasopoulos, Athanasios Manolis, Michael Doumas*

Journal Name: Current Vascular Pharmacology

Volume 19 , Issue 3 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Erectile dysfunction (ED) is a major health problem that affects a significant proportion of the general population, and its prevalence is even higher in patients with CV risk factors and/or disease. ED and cardiovascular (CV) disease share several common pathophysiological mechanisms, and thus, the potential role of ED as a predictor of CV events has emerged as a significant research aspect.

Objective: The purpose of this review is to present and critically discuss data assessing the relation between ED and CV disease and the potential predictive value of ED for CV events.

Methods: A comprehensive review of the literature has been performed to identify studies evaluating the association between ED and CV disease.

Results: Several cross-sectional and prospective studies have examined the association between ED and CV disease and found an increased prevalence of ED in patients with CV disease. ED was shown to independently predict future CV events. Importantly, ED was found to precede the development of overt coronary artery disease (CAD) by 3 to 5 years, offering a “time window” to properly manage these patients before the clinical manifestation of CAD. Phosphodiesterase type 5 inhibitors are the first-line treatment option for ED and were shown to be safe in terms of CV events in patients with and without CV disease.

Conclusion: Accumulating evidence supports a strong predictive role of ED for CV events. Early identification of ED could allow for the optimal management of these patients to reduce the risk for a CV event to occur.

Keywords: Erectile dysfunction, cardiovascular disease, cardiovascular risk, cardiovascular predictor, PDE-5 inhibitors, heart disease.

[1]
Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163(2): 460-3.
[http://dx.doi.org/10.1016/S0022-5347(05)67900-1] [PMID: 10647654]
[2]
Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013; 34(27): 2034-46.
[http://dx.doi.org/10.1093/eurheartj/eht112] [PMID: 23616415]
[3]
Doumas M, Tsiodras S, Tsakiris A, et al. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens 2006; 24(12): 2387-92.
[http://dx.doi.org/10.1097/01.hjh.0000251898.40002.5b] [PMID: 17082720]
[4]
Viigimaa M, Vlachopoulos C, Lazaridis A, Doumas M. Management of erectile dysfunction in hypertension: Tips and tricks. World J Cardiol 2014; 6(9): 908-15.
[http://dx.doi.org/10.4330/wjc.v6.i9.908] [PMID: 25276292]
[5]
Menezes A, Artham S, Lavie CJ, Milani RV, O’Keefe J. Erectile dysfunction and cardiovascular disease. Postgrad Med 2011; 123(3): 7-16.
[http://dx.doi.org/10.3810/pgm.2011.05.2279] [PMID: 21566411]
[6]
Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Stefanadis C. The triad: erectile dysfunction--endothelial dysfunction--cardiovascular disease. Curr Pharm Des 2008; 14(35): 3700-14.
[http://dx.doi.org/10.2174/138161208786898716] [PMID: 19128223]
[7]
Montorsi P, Montorsi F, Schulman CC. Is erectile dysfunction the “tip of the iceberg” of a systemic vascular disorder? Eur Urol 2003; 44(3): 352-4.
[http://dx.doi.org/10.1016/S0302-2838(03)00307-5] [PMID: 12932935]
[8]
Jackson G, Boon N, Eardley I, et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus. Int J Clin Pract 2010; 64(7): 848-57.
[http://dx.doi.org/10.1111/j.1742-1241.2010.02410.x] [PMID: 20584218]
[9]
Katsiki N, Athyros VG, Karagiannis A, Wierzbicki AS, Mikhailidis DP. Should we expand the concept of coronary heart disease equiv-alents? Curr Opin Cardiol 2014; 29(4): 389-95.
[http://dx.doi.org/10.1097/HCO.0000000000000068] [PMID: 25029454]
[10]
Doumas M, Lazaridis A, Katsiki N, Athyros V. PDE-5 inhibitors: clinical points. Curr Drug Targets 2015; 16(5): 420-6.
[http://dx.doi.org/10.2174/1389450115666141111111301] [PMID: 25392015]
[11]
NIH Consensus Conference Impotence. JAMA 1993; 270(1): 83-90.
[http://dx.doi.org/10.1001/jama.1993.03510010089036] [PMID: 8510302]
[12]
Bachman GA, Avci D. Evaluation and management of female sexual dysfunction. Endocrinologist 2004; 14: 337-45.
[http://dx.doi.org/10.1097/01.ten.0000146394.84092.1b]
[13]
Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL. Prevalence of erectile dysfunction: a systematic review of population-based studies. Int J Impot Res 2002; 14(6): 422-32.
[http://dx.doi.org/10.1038/sj.ijir.3900905] [PMID: 12494273]
[14]
Shabsigh R, Perelman MA, Laumann EO, Lockhart DC. Drivers and barriers to seeking treatment for erectile dysfunction: a comparison of six countries. BJU Int 2004; 94(7): 1055-65.
[http://dx.doi.org/10.1111/j.1464-410X.2004.05104.x] [PMID: 15541128]
[15]
Doumas M, Boutari C. Erectile dysfunction: definition and size of the problemESC CardioMed 3rd ed Serruys, PW. 2018.
[16]
Laumann EO, Nicolosi A, Glasser DB, et al. GSSAB Investigators’ Group. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17(1): 39-57.
[http://dx.doi.org/10.1038/sj.ijir.3901250] [PMID: 15215881]
[17]
Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. Men’s Attitudes to Life Events and Sexuality (MALES) Study. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20(5): 607-17.
[http://dx.doi.org/10.1185/030079904125003467] [PMID: 15171225]
[18]
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151(1): 54-61.
[http://dx.doi.org/10.1016/S0022-5347(17)34871-1] [PMID: 8254833]
[19]
Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol 2004; 171(6 Pt 1): 2341-5.
[http://dx.doi.org/10.1097/01.ju.0000125198.32936.38] [PMID: 15126817]
[20]
Bacon CG, Mittleman MA, Kawachi I, Giovannucci E, Glasser DB, Rimm EB. A prospective study of risk factors for erectile dysfunction. J Urol 2006; 176(1): 217-21.
[http://dx.doi.org/10.1016/S0022-5347(06)00589-1] [PMID: 16753404]
[21]
Kupelian V, Link CL, Rosen RC, McKinlay JB. Socioeconomic status, not race/ethnicity, contributes to variation in the prevalence of erectile dysfunction: results from the Boston Area Community Health (BACH) Survey. J Sex Med 2008; 5(6): 1325-33.
[http://dx.doi.org/10.1111/j.1743-6109.2008.00822.x] [PMID: 18410305]
[22]
Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol 2003; 170(2 Pt 2): S46-50.
[http://dx.doi.org/10.1097/01.ju.0000075055.34506.59] [PMID: 12853773]
[23]
Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J 2006; 27(22): 2632-9.
[http://dx.doi.org/10.1093/eurheartj/ehl142] [PMID: 16854949]
[24]
Gandaglia G, Briganti A, Jackson G, et al. A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol 2014; 65(5): 968-78.
[http://dx.doi.org/10.1016/j.eururo.2013.08.023] [PMID: 24011423]
[25]
Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44(3): 360-4.
[http://dx.doi.org/10.1016/S0302-2838(03)00305-1] [PMID: 12932937]
[26]
Gandaglia G, Briganti A, Montorsi P, et al. Erectile dysfunction in coronary artery disease and heart failureErectile dysfunction in hy-pertension and cardiovascular disease. Switzerland: Springer International Publishing 2015; pp. 59-71.
[http://dx.doi.org/10.1007/978-3-319-08272-1_7]
[27]
Alberti L, Torlasco C, Lauretta L, et al. Erectile dysfunction in heart failure patients: a critical reappraisal. Andrology 2013; 1(2): 177-91.
[http://dx.doi.org/10.1111/j.2047-2927.2012.00048.x] [PMID: 23339018]
[28]
Apostolo A, Vignati C, Brusoni D, et al. Erectile dysfunction in heart failure: correlation with severity, exercise performance, comorbidities, and heart failure treatment. J Sex Med 2009; 6(10): 2795-805.
[http://dx.doi.org/10.1111/j.1743-6109.2009.01416.x] [PMID: 19674255]
[29]
Doumas M, Tsakiris A, Douma S, et al. Factors affecting the increased prevalence of erectile dysfunction in Greek hypertensive compared with normotensive subjects. J Androl 2006; 27(3): 469-77.
[http://dx.doi.org/10.2164/jandrol.04191] [PMID: 16339456]
[30]
Doumas M, Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens (Greenwich) 2006; 8(4): 269-74.
[http://dx.doi.org/10.1111/j.1524-6175.2006.04708.x] [PMID: 16596030]
[31]
Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens 2008; 26(11): 2074-84.
[http://dx.doi.org/10.1097/HJH.0b013e32830dd0c6] [PMID: 18854743]
[32]
Viigimaa M, Doumas M, Vlachopoulos C, et al. European Society of Hypertension Working Group on Sexual Dysfunction Hypertension and sexual dysfunction: time to act. J Hypertens 2011; 29(2): 403-7.
[http://dx.doi.org/10.1097/HJH.0b013e328342c659] [PMID: 21178782]
[33]
Viigimaa M, Vlachopoulos C, Doumas M, Eds. Erectile dysfunction in hypertension and cardiovascular disease. Switzerland: Springer International Publishing 2015; pp. 1-249.
[http://dx.doi.org/10.1007/978-3-319-08272-1]
[34]
Burke JP, Jacobson DJ, McGree ME, et al. Diabetes and sexual dysfunction: results from the Olmsted County study of urinary symptoms and health status among men. J Urol 2007; 177(4): 1438-42.
[http://dx.doi.org/10.1016/j.juro.2006.11.059] [PMID: 17382749]
[35]
Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 2002; 25(8): 1458-63.
[http://dx.doi.org/10.2337/diacare.25.8.1458] [PMID: 12145250]
[36]
Penson DF, Latini DM, Lubeck DP, et al. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the ExCEED database. Diabetes Care 2003; 26: 1093-9.
[http://dx.doi.org/10.2337/diacare.26.4.1093] [PMID: 12663579]
[37]
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338(20): 1397-404.
[http://dx.doi.org/10.1056/NEJM199805143382001] [PMID: 9580646]
[38]
Nikolaidou B, Nouris C, Lazaridis A, et al. Diabetes mellitus and erectile dysfunctionErectile dysfunction in hypertension and cardi-ovascular disease. Switzerland: Springer International Publishing 2015; pp. 119-28.
[39]
Kaya E, Sikka SC, Gur S. A comprehensive review of metabolic syndrome affecting erectile dysfunction. J Sex Med 2015; 12(4): 856-75.
[http://dx.doi.org/10.1111/jsm.12828] [PMID: 25675988]
[40]
Esposito K, Giugliano F, Ciotola M, De Sio M, D’Armiento M, Giugliano D. Obesity and sexual dysfunction, male and female. Int J Impot Res 2008; 20(4): 358-65.
[http://dx.doi.org/10.1038/ijir.2008.9] [PMID: 18401349]
[41]
Diaz-Arjonilla M, Schwarcz M, Swerdloff RS, Wang C. Obesity, low testosterone levels and erectile dysfunction. Int J Impot Res 2009; 21(2): 89-98.
[http://dx.doi.org/10.1038/ijir.2008.42] [PMID: 18843273]
[42]
Smith NJ, Sak SC, Baldo O, Eardley I. The prevalence of newly diagnosed hyperlipidaemia in men with erectile dysfunction. BJU Int 2007; 100(2): 357-61.
[http://dx.doi.org/10.1111/j.1464-410X.2007.06988.x] [PMID: 17550417]
[43]
Gündüz MI, Gümüs BH, Sekuri C. Relationship between metabolic syndrome and erectile dysfunction. Asian J Androl 2004; 6(4): 355-8.
[PMID: 15546029]
[44]
Vrentzos GE, Paraskevas KI, Mikhailidis DP. Dyslipidemia as a risk factor for erectile dysfunction. Curr Med Chem 2007; 14(16): 1765-70.
[http://dx.doi.org/10.2174/092986707781058931] [PMID: 17627514]
[45]
Pittaras A, Avranas K, Imprialos K, et al. The association between dyslipidemia and its treatment with erectile dysfunction Erectile dysfunction in hypertension and cardiovascular disease. Switzerland: Springer International Publishing 2015; pp. 129-38.
[http://dx.doi.org/10.1007/978-3-319-08272-1_13]
[46]
Mirone V, Imbimbo C, Bortolotti A, et al. Cigarette smoking as risk factor for erectile dysfunction: results from an Italian epidemiological study. Eur Urol 2002; 41(3): 294-7.
[http://dx.doi.org/10.1016/S0302-2838(02)00005-2] [PMID: 12180231]
[47]
Shabsigh R, Fishman IJ, Schum C, Dunn JK. Cigarette smoking and other vascular risk factors in vasculogenic impotence. Urology 1991; 38(3): 227-31.
[http://dx.doi.org/10.1016/S0090-4295(91)80350-G] [PMID: 1887536]
[48]
Tengs TO, Osgood ND. The link between smoking and impotence: two decades of evidence. Prev Med 2001; 32(6): 447-52.
[http://dx.doi.org/10.1006/pmed.2001.0830] [PMID: 11394947]
[49]
Cao S, Yin X, Wang Y, Zhou H, Song F, Lu Z. Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLoS One 2013; 8(4)e60443
[http://dx.doi.org/10.1371/journal.pone.0060443] [PMID: 23573257]
[50]
Vlachopoulos C, Rokkas K, Ioakeimidis N, Stefanadis C. Inflammation, metabolic syndrome, erectile dysfunction, and coronary artery disease: common links. Eur Urol 2007; 52(6): 1590-600.
[http://dx.doi.org/10.1016/j.eururo.2007.08.004] [PMID: 17707576]
[51]
Vlachopoulos C, Aznaouridis K, Ioakeimidis N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 2006; 27(22): 2640-8.
[http://dx.doi.org/10.1093/eurheartj/ehl341] [PMID: 17056702]
[52]
Kratzik CW, Schatzl G, Lunglmayr G, Rücklinger E, Huber J. The impact of age, body mass index and testosterone on erectile dysfunction. J Urol 2005; 174(1): 240-3.
[http://dx.doi.org/10.1097/01.ju.0000162049.95483.51] [PMID: 15947646]
[53]
Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001; 281(6): E1172-81.
[http://dx.doi.org/10.1152/ajpendo.2001.281.6.E1172] [PMID: 11701431]
[54]
Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158(5): 1764-7.
[http://dx.doi.org/10.1016/S0022-5347(01)64123-5] [PMID: 9334596]
[55]
Bodie J, Lewis J, Schow D, Monga M. Laboratory evaluations of erectile dysfunction: an evidence based approach. J Urol 2003; 169(6): 2262-4.
[http://dx.doi.org/10.1097/01.ju.0000063940.19080.58] [PMID: 12771765]
[56]
Earle CM, Stuckey BG. Biochemical screening in the assessment of erectile dysfunction: what tests decide future therapy? Urology 2003; 62(4): 727-31.
[http://dx.doi.org/10.1016/S0090-4295(03)00508-9] [PMID: 14550452]
[57]
Farias JM, Tinetti M, Khoury M, Umpierrez GE. Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. J Clin Endocrinol Metab 2014; 99(12): 4698-703.
[http://dx.doi.org/10.1210/jc.2014-2585] [PMID: 25322269]
[58]
Lee WC, Kim MT, Ko KT, et al. Relationship between serum testosterone and cardiovascular disease risk determined using the Framingham Risk Score in male patients with sexual dysfunction. World J Mens Health 2014; 32(3): 139-44.
[http://dx.doi.org/10.5534/wjmh.2014.32.3.139] [PMID: 25606562]
[59]
Hu X, Rui L, Zhu T, et al. Low testosterone level in middle-aged male patients with coronary artery disease. Eur J Intern Med 2011; 22(6): e133-6.
[http://dx.doi.org/10.1016/j.ejim.2011.08.016] [PMID: 22075298]
[60]
Li L, Guo CY, Jia EZ, et al. Testosterone is negatively associated with the severity of coronary atherosclerosis in men. Asian J Androl 2012; 14(6): 875-8.
[http://dx.doi.org/10.1038/aja.2012.95] [PMID: 23042448]
[61]
Alkamel A, Shafiee A, Jalali A, Boroumand M, Nozari Y. The association between premature coronary artery disease and level of testosterone in young adult males. Arch Iran Med 2014; 17(8): 545-50.
[PMID: 25065277]
[62]
Corona G, Rastrelli G, Monami M, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165(5): 687-701.
[http://dx.doi.org/10.1530/EJE-11-0447] [PMID: 21852391]
[63]
Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96(10): 3007-19.
[http://dx.doi.org/10.1210/jc.2011-1137] [PMID: 21816776]
[64]
Vlachopoulos C, Rokkas K, Ioakeimidis N, et al. Prevalence of asymptomatic coronary artery disease in men with vasculogenic erectile dysfunction: a prospective angiographic study. Eur Urol 2005; 48(6): 996-1002.
[http://dx.doi.org/10.1016/j.eururo.2005.08.002] [PMID: 16174548]
[65]
Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004; 16(4): 350-3.
[http://dx.doi.org/10.1038/sj.ijir.3901174] [PMID: 14985780]
[66]
Ponholzer A, Temml C, Obermayr R, Wehrberger C, Madersbacher S. Is erectile dysfunction an indicator for increased risk of coronary heart disease and stroke? Eur Urol 2005; 48(3): 512-8.
[http://dx.doi.org/10.1016/j.eururo.2005.05.014] [PMID: 15998563]
[67]
Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294(23): 2996-3002.
[http://dx.doi.org/10.1001/jama.294.23.2996] [PMID: 16414947]
[68]
Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res 2008; 20(1): 92-9.
[http://dx.doi.org/10.1038/sj.ijir.3901604] [PMID: 17728804]
[69]
Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med 2009; 6(9): 2445-54.
[http://dx.doi.org/10.1111/j.1743-6109.2009.01354.x] [PMID: 19538544]
[70]
Banks E, Joshy G, Abhayaratna WP, et al. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. PLoS Med 2013; 10(1)e1001372
[http://dx.doi.org/10.1371/journal.pmed.1001372] [PMID: 23382654]
[71]
Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008; 51(21): 2045-50.
[http://dx.doi.org/10.1016/j.jacc.2008.02.051] [PMID: 18498959]
[72]
Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008; 51(21): 2040-4.
[http://dx.doi.org/10.1016/j.jacc.2007.10.069] [PMID: 18498958]
[73]
Batty GD, Li Q, Czernichow S, et al. . ADVANCE Collaborative Group.. Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation) trial. J Am Coll Cardiol 2010; 56(23): 1908-13.
[http://dx.doi.org/10.1016/j.jacc.2010.04.067] [PMID: 21109113]
[74]
Böhm M, Baumhäkel M, Teo K, et al. ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ongoing telmisartan alone and in combination with Ramipril global endpoint trial/telmisartan randomized assessment study in ace intolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) Trials. Circulation 2010; 121(12): 1439-46.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.864199] [PMID: 20231536]
[75]
Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J Am Coll Cardiol 2011; 58(13): 1378-85.
[http://dx.doi.org/10.1016/j.jacc.2011.06.024] [PMID: 21920268]
[76]
Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6(1): 99-109.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.112.966903] [PMID: 23300267]
[77]
Araujo AB, Hall SA, Ganz P, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score? J Am Coll Cardiol 2010; 55(4): 350-6.
[http://dx.doi.org/10.1016/j.jacc.2009.08.058] [PMID: 20117441]
[78]
La Torre A, Giupponi G, Duffy D, Conca A, Catanzariti D. Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs. Pharmacopsychiatry 2015; 48(1): 1-6.
[PMID: 25405774]
[79]
Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros VG. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Curr Vasc Pharmacol 2018; 16(2): 130-42.
[http://dx.doi.org/10.2174/1570161115666170609101502] [PMID: 28595561]
[80]
Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep 2012; 14(4): 285-92.
[http://dx.doi.org/10.1007/s11906-012-0276-5] [PMID: 22581395]
[81]
Cordero A, Bertomeu-Martínez V, Mazón P, et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther 2010; 28(1): 15-22.
[http://dx.doi.org/10.1111/j.1755-5922.2009.00123.x] [PMID: 20074255]
[82]
Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001; 14(1): 27-31.
[http://dx.doi.org/10.1016/S0895-7061(00)01214-0] [PMID: 11206674]
[83]
Fogari R, Preti P, Derosa G, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58(3): 177-80.
[http://dx.doi.org/10.1007/s00228-002-0456-3] [PMID: 12107602]
[84]
Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11(10): 1244-7.
[http://dx.doi.org/10.1016/S0895-7061(98)00139-3] [PMID: 9799042]
[85]
Doumas M, Tsakiris A, Douma S, et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 2006; 8(2): 177-82.
[http://dx.doi.org/10.1111/j.1745-7262.2006.00076.x] [PMID: 16491268]
[86]
Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007; 34(4): 327-31.
[http://dx.doi.org/10.1111/j.1440-1681.2007.04551.x] [PMID: 17324145]
[87]
Boydak B, Nalbantgil S, Fici F, et al. A randomized comparison of the effects of nebivolol and atenolol with and without çhlorthalidone on the sexual function of hypertensive men. Clin Drug Investig 2005; 25(6): 409-16.
[http://dx.doi.org/10.2165/00044011-200525060-00006] [PMID: 17532681]
[88]
Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005; 18(8): 1060-6.
[http://dx.doi.org/10.1016/j.amjhyper.2005.03.733] [PMID: 16296572]
[89]
Grimm RH Jr, Grandits GA, Prineas RJ, et al. Treatment of Mild Hypertension Study (TOMHS). Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Hypertension 1997; 29(1 Pt 1): 8-14.
[http://dx.doi.org/10.1161/01.HYP.29.1.8] [PMID: 9039073]
[90]
Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981; 2(8246): 539-43.
[PMID: 6115999]
[91]
Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991; 114(8): 613-20.
[http://dx.doi.org/10.7326/0003-4819-114-8-613] [PMID: 2003706]
[92]
Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the antihypertensive treatment and lipid profile in a north of Sweden efficacy evaluation (ALPINE study). J Hypertens 2003; 21(8): 1563-74.
[http://dx.doi.org/10.1097/00004872-200308000-00022] [PMID: 12872052]
[93]
Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six anti-hypertensive agents with placebo: the Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. N Engl J Med 1993; 328: 914-21.
[http://dx.doi.org/10.1056/NEJM199304013281303] [PMID: 8446138]
[94]
Athyros VG, Kakafika AI, Tziomalos K, Karagiannis A, Mikhailidis DP. Pleiotropic effects of statins--clinical evidence. Curr Pharm Des 2009; 15(5): 479-89.
[http://dx.doi.org/10.2174/138161209787315729] [PMID: 19199976]
[95]
Carvajal A, Macias D, Sáinz M, et al. HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. Drug Saf 2006; 29(2): 143-9.
[http://dx.doi.org/10.2165/00002018-200629020-00004] [PMID: 16454541]
[96]
Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database. Drug Saf 2009; 32(7): 591-7.
[http://dx.doi.org/10.2165/00002018-200932070-00005] [PMID: 19530745]
[97]
Bruckert E, Giral P, Heshmati HM, Turpin G. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther 1996; 21(2): 89-94.
[http://dx.doi.org/10.1111/j.1365-2710.1996.tb00006.x] [PMID: 8809645]
[98]
Hall SA, Kupelian V, Rosen RC, et al. Is hyperlipidemia or its treatment associated with erectile dysfunction: Results from the Boston area community health (BACH) survey. J Sex Med 2009; 6(5): 1402-13.
[http://dx.doi.org/10.1111/j.1743-6109.2008.01207.x] [PMID: 19210709]
[99]
Davis R, Reveles KR, Ali SK, Mortensen EM, Frei CR, Mansi I. Statins and male sexual health: a retrospective cohort analysis. J Sex Med 2015; 12(1): 158-67.
[http://dx.doi.org/10.1111/jsm.12745] [PMID: 25421152]
[100]
Chou CY, Yang YF, Chou YJ, Hu HY, Huang N. Statin use and incident erectile dysfunction--A nationwide propensity-matched cohort study in Taiwan. Int J Cardiol 2016; 202: 883-8.
[http://dx.doi.org/10.1016/j.ijcard.2015.10.012] [PMID: 26476986]
[101]
Corona G, Boddi V, Balercia G, et al. The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction. J Sex Med 2010; 7(4 Pt 1): 1547-56.
[http://dx.doi.org/10.1111/j.1743-6109.2009.01698.x] [PMID: 20141585]
[102]
Solomon H, Samarasinghe YP, Feher MD, et al. Erectile dysfunction and statin treatment in high cardiovascular risk patients. Int J Clin Pract 2006; 60(2): 141-5.
[http://dx.doi.org/10.1111/j.1742-1241.2006.00793.x] [PMID: 16451283]
[103]
Londoño DC, Slezak JM, Quinn VP, Van Den Eeden SK, Loo RK, Jacobsen SJ. Population-based study of erectile dysfunction and polypharmacy. BJU Int 2012; 110(2): 254-9.
[http://dx.doi.org/10.1111/j.1464-410X.2011.10761.x] [PMID: 22085284]
[104]
Trivedi D, Kirby M, Wellsted DM, et al. Can simvastatin improve erectile function and health-related quality of life in men aged ≥40 years with erectile dysfunction? results of the erectile dysfunction and statins trial.[ISRCTN66772971] BJU Int 2013; 111(2): 324-33.[ISRCTN66772971].
[http://dx.doi.org/10.1111/j.1464-410X.2012.11241.x] [PMID: 22686292]
[105]
Trivedi D, Wellsted DM, Collard JB, Kirby M. Simvastatin improves the sexual health-related quality of life in men aged 40 years and over with erectile dysfunction: additional data from the erectile dysfunction and statin trial. BMC Urol 2014; 14: 24.
[http://dx.doi.org/10.1186/1471-2490-14-24] [PMID: 24593269]
[106]
Mastalir ET, Carvalhal GF, Portal VL. The effect of simvastatin in penile erection: a randomized, double-blind, placebo-controlled clinical trial (Simvastatin treatment for erectile dysfunction-STED TRIAL). Int J Impot Res 2011; 23(6): 242-8.
[http://dx.doi.org/10.1038/ijir.2011.33] [PMID: 21716297]
[107]
Herrmann HC, Levine LA, Macaluso J Jr, et al. Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results. J Sex Med 2006; 3(2): 303-8.
[http://dx.doi.org/10.1111/j.1743-6109.2005.00156.x] [PMID: 16490024]
[108]
Dadkhah F, Safarinejad MR, Asgari MA, Hosseini SY, Lashay A, Amini E. Atorvastatin improves the response to sildenafil in hyper-cholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res 2010; 22(1): 51-60.
[http://dx.doi.org/10.1038/ijir.2009.48] [PMID: 19865092]
[109]
El-Sisi AA, Hegazy SK, Salem KA. AbdElkawy KS. Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase. Int J Impot Res 2013; 25(4): 143-8.
[http://dx.doi.org/10.1038/ijir.2012.46] [PMID: 23324897]
[110]
Bank AJ, Kelly AS, Kaiser DR, et al. The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction. Vasc Med 2006; 11(4): 251-7.
[http://dx.doi.org/10.1177/1358863x06072221] [PMID: 17390549]
[111]
Gokkaya SC, Ozden C, Levent Ozdal O, Hakan Koyuncu H, Guzel O, Memis A. Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction. Scand J Urol Nephrol 2008; 42(5): 437-40.
[http://dx.doi.org/10.1080/00365590801950279] [PMID: 18609275]
[112]
Gokce MI, Gülpınar Ö, Öztürk E, Güleç S, Yaman Ö. Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study. Int Urol Nephrol 2012; 44(3): 683-7.
[http://dx.doi.org/10.1007/s11255-012-0126-z] [PMID: 22252217]
[113]
Nurkalem Z, Yildirimtürk Ö, Özcan KS, et al. The effect of rosuvastatin and atorvastatin on erectile dysfunction in hypercholesterolaemic patients. Kardiol Pol 2014; 72(3): 275-9.
[http://dx.doi.org/10.5603/KP.a2013.0287] [PMID: 24142756]
[114]
Cui Y, Zong H, Yan H, Zhang Y. The effect of statins on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2014; 11(6): 1367-75.
[http://dx.doi.org/10.1111/jsm.12497] [PMID: 24628781]
[115]
Cai X, Tian Y, Wu T, Cao CX, Bu SY, Wang KJ. The role of statins in erectile dysfunction: a systematic review and meta-analysis. Asian J Androl 2014; 16(3): 461-6.
[http://dx.doi.org/10.4103/1008-682X.123678] [PMID: 24556747]
[116]
Kostis JB, Dobrzynski JM. The effect of statins on erectile dysfunction: a meta-analysis of randomized trials. J Sex Med 2014; 11(7): 1626-35.
[http://dx.doi.org/10.1111/jsm.12521] [PMID: 24684744]
[117]
Labazi H, Wynne BM, Tostes R, Webb RC. Metformin treatment improves erectile function in an angiotensin II model of erectile dysfunction. J Sex Med 2013; 10(9): 2154-64.
[http://dx.doi.org/10.1111/jsm.12245] [PMID: 23889981]
[118]
Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction in a rat model of type 2 diabetes mellitus. BJU Int 2006; 98(1): 116-24.
[http://dx.doi.org/10.1111/j.1464-410X.2006.06268.x] [PMID: 16831155]
[119]
Aliperti LA, Lasker GF, Hagan SS, et al. Efficacy of pioglitazone on erectile function recovery in a rat model of cavernous nerve injury. Urology 2014; 84(5): 1122-7.
[http://dx.doi.org/10.1016/j.urology.2014.07.033] [PMID: 25443915]
[120]
Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Ageing-related corpora veno-occlusive dysfunction in the rat is ameliorated by pioglitazone. BJU Int 2007; 100(4): 867-74.
[http://dx.doi.org/10.1111/j.1464-410X.2007.07070.x] [PMID: 17662078]
[121]
Yue L, Xu JL, Dong J, et al. Regulatory effect of liraglutide on the expression of eNOS in the corpus cavernosum of diabetic rats. Zhonghua Nan Ke Xue 2016; 22(3): 212-8.
[PMID: 27172659]
[122]
Ricci E, Parazzini F, Mirone V, et al. Current drug use as risk factor for erectile dysfunction: results from an Italian epidemiological study. Int J Impot Res 2003; 15(3): 221-4.
[http://dx.doi.org/10.1038/sj.ijir.3901008] [PMID: 12904809]
[123]
Rey-Valzacchi GJ, Costanzo PR, Finger LA, et al. Addition of metformin to sildenafil treatment for erectile dysfunction in eugonadal nondiabetic men with insulin resistance. A prospective, randomized, double-blind pilot study. J Androl 2012; 33(4): 608-14.
[http://dx.doi.org/10.2164/jandrol.111.013714] [PMID: 22016348]
[124]
Gholamine B, Shafiei M, Motevallian M, Mahmoudian M. Effects of pioglitazone on erectile dysfunction in sildenafil poor-responders: a randomized, controlled study. J Pharm Pharm Sci 2008; 11(1): 22-31.
[http://dx.doi.org/10.18433/J3TG6H] [PMID: 18445362]
[125]
Giagulli VA, Carbone MD, Ramunni MI, et al. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism. Andrology 2015; 3(6): 1094-103.
[http://dx.doi.org/10.1111/andr.12099] [PMID: 26447645]
[126]
Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013; 63(5): 902-12.
[http://dx.doi.org/10.1016/j.eururo.2013.01.012] [PMID: 23395275]
[127]
Boulton AJ, Selam JL, Sweeney M, Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia 2001; 44(10): 1296-301.
[http://dx.doi.org/10.1007/s001250100656] [PMID: 11692178]
[128]
Stuckey BG, Jadzinsky MN, Murphy LJ, et al. Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. Diabetes Care 2002; 25: 2159-64.
[PMID: 12547849]
[129]
Young JM, Bennett C, Gilhooly P, Wessells H, Ramos DE. Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. Urology 2002; 60(2)(Suppl. 2): 39-48.
[http://dx.doi.org/10.1016/S0090-4295(02)01689-8] [PMID: 12414332]
[130]
Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23(6): 763-71.
[PMID: 12399521]
[131]
van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple anti-hypertensives. J Sex Med 2005; 2(6): 856-64.
[http://dx.doi.org/10.1111/j.1743-6109.2005.00150.x] [PMID: 16422810]
[132]
Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil Diabetes Study Group. Vardenafil, a new phos-phodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003; 26(3): 777-83.
[http://dx.doi.org/10.2337/diacare.26.3.777] [PMID: 12610037]
[133]
Ziegler D, Merfort F, Van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3(5): 883-91.
[http://dx.doi.org/10.1111/j.1743-6109.2006.00295.x] [PMID: 16942532]
[134]
Valiquette L, Montorsi F, Auerbach S. Vardenafil Study Group. First-dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY-I. Int J Clin Pract 2006; 60(11): 1378-85.
[http://dx.doi.org/10.1111/j.1742-1241.2006.01170.x] [PMID: 17073835]
[135]
Valiquette L, Montorsi F, Auerbach S. Vardenafil Study Group. Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II. Can Urol Assoc J 2008; 2(3): 187-95.
[http://dx.doi.org/10.5489/cuaj.590] [PMID: 18682779]
[136]
Stief C, Porst H, Sáenz De Tejada I, Ulbrich E, Beneke M. Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004; 58(3): 230-9.
[http://dx.doi.org/10.1111/j.1368-5031.2004.00128.x] [PMID: 15117088]
[137]
Miner M, Gilderman L, Bailen J, et al. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008; 5(6): 1455-67.
[http://dx.doi.org/10.1111/j.1743-6109.2008.00820.x] [PMID: 18373526]
[138]
Sperling H, Gittelman M, Norenberg C, Ulbrich E, Ewald S. Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction in elderly men and those with underlying conditions: an integrated analysis of two pivotal trials. J Sex Med 2011; 8(1): 261-71.
[http://dx.doi.org/10.1111/j.1743-6109.2010.02005.x] [PMID: 20807322]
[139]
Goldstein I, Kim E, Steers WD, et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007; 4(1): 166-75.
[http://dx.doi.org/10.1111/j.1743-6109.2006.00402.x] [PMID: 17233782]
[140]
Sáenz de Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25(12): 2159-64.
[http://dx.doi.org/10.2337/diacare.25.12.2159] [PMID: 12453954]
[141]
McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2(3): 415-25.
[http://dx.doi.org/10.1111/j.1743-6109.2005.20360.x] [PMID: 16422874]
[142]
Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol 1999; 83(5A): 29-34.
[http://dx.doi.org/10.1016/S0002-9149(99)00045-4] [PMID: 10078540]
[143]
DeBusk RF, Pepine CJ, Glasser DB, Shpilsky A, DeRiesthal H, Sweeney M. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004; 93(2): 147-53.
[http://dx.doi.org/10.1016/j.amjcard.2003.09.030] [PMID: 14715338]
[144]
Olsson AM, Persson CA. Swedish Sildenafil Investigators Group. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease. Int J Clin Pract 2001; 55(3): 171-6.
[PMID: 11351770]
[145]
Van Ahlen H, Zumbé J, Stauch K, Hanisch JU. The Real-Life Safety and Efficacy of vardenafil (REALISE) study: results in men from Europe and overseas with erectile dysfunction and cardiovascular or metabolic conditions. J Sex Med 2010; 7(9): 3161-9.
[http://dx.doi.org/10.1111/j.1743-6109.2010.01921.x] [PMID: 20646189]
[146]
Katz SD, Parker JD, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005; 95(1): 36-42.
[http://dx.doi.org/10.1016/j.amjcard.2004.08.060] [PMID: 15619391]
[147]
Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011; 4(1): 8-17.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.110.944694] [PMID: 21036891]
[148]
Urbanowicz T, Straburzyńska-Migaj E, Katyńska I, et al. Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil. Ann Transplant 2014; 19: 325-30.
[http://dx.doi.org/10.12659/AOT.890657] [PMID: 25007352]
[149]
Wu X, Yang T, Zhou Q, Li S, Huang L. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis. Eur J Heart Fail 2013.[ahead of print].
[http://dx.doi.org/10.1002/ejhf.47] [PMID: 24464734]
[150]
Redfield MM, Chen HH, Borlaug BA, et al. RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309(12): 1268-77.
[http://dx.doi.org/10.1001/jama.2013.2024] [PMID: 23478662]
[151]
Zhuang XD, Long M, Li F, Hu X, Liao XX, Du ZM. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 2014; 172(3): 581-7.
[http://dx.doi.org/10.1016/j.ijcard.2014.01.102] [PMID: 24534379]
[152]
The Lancet editorial team. Viagra’s licence and the internet. Lancet 1998; 352: 751.
[http://dx.doi.org/10.1016/S0140-6736(97)91037-0]
[153]
Feenstra J, van Drie-Pierik RJHM, Laclé CF, Stricker BHC. Acute myocardial infarction associated with sildenafil. Lancet 1998; 352(9132): 957-8.
[http://dx.doi.org/10.1016/S0140-6736(98)00015-4] [PMID: 9752820]
[154]
Cheitlin MD, Hutter AM Jr, Brindis RG, et al. American College of Cardiology/American Heart Association. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999; 33(1): 273-82.
[http://dx.doi.org/10.1016/S0735-1097(98)00656-1] [PMID: 9935041]
[155]
Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10(2): 69-73.
[http://dx.doi.org/10.1038/sj.ijir.3900354] [PMID: 9647940]
[156]
Kloner RA. Cardiovascular risk and sildenafil. Am J Cardiol 2000; 86(2)(Suppl.): 57F-61F.
[http://dx.doi.org/10.1016/S0002-9149(00)00895-X] [PMID: 10899281]
[157]
Shakir SA, Wilton LV, Boshier A, Layton D, Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001; 322(7287): 651-2.
[http://dx.doi.org/10.1136/bmj.322.7287.651] [PMID: 11250850]
[158]
Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol 2002; 89(11): 1331-4.
[http://dx.doi.org/10.1016/S0002-9149(02)02342-1] [PMID: 12031744]
[159]
Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010; 64(2): 240-55.
[http://dx.doi.org/10.1111/j.1742-1241.2009.02254.x] [PMID: 19900167]
[160]
Tsertsvadze A, Yazdi F, Fink HA, et al. Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. Urology 2009; 74(4): 831-836 e8.
[http://dx.doi.org/10.1016/j.urology.2009.04.026] [PMID: 19592078]
[161]
Buranakitjaroen P, Mangklabruks A, Leungwattanakij S, et al. Thai-Malaysian-Singapore Erectile Dysfunction Study Group (THAMES Group).. Efficacy and safety of sildenafil in Asian males with erectile dysfunction and cardiovascular risk. J Med Assoc Thai 2007; 90(6): 1100-8.
[PMID: 17624203]
[162]
Pickering TG, Shepherd AM, Puddey I, et al. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial. Am J Hypertens 2004; 17(12 Pt 1): 1135-42.
[http://dx.doi.org/10.1016/j.amjhyper.2004.07.004] [PMID: 15607620]
[163]
Kloner RA, Jackson G, Hutter AM, et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol 2006; 97(12): 1778-84.
[http://dx.doi.org/10.1016/j.amjcard.2005.12.073] [PMID: 16765134]
[164]
Hazell L, Boshier A, Harris S, Wilton LV, Shakir SAW. An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease. BJU Int 2007; 99(2): 387-93.
[http://dx.doi.org/10.1111/j.1464-410X.2007.06581.x] [PMID: 17313426]
[165]
Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 in-hibitors. J Sex Med 2012; 9(1): 265-70.
[http://dx.doi.org/10.1111/j.1743-6109.2011.02537.x] [PMID: 22023666]
[166]
Vlachopoulos C, Ioakeimidis N, Rokkas K, Stefanadis C. Cardiovascular effects of phosphodiesterase type 5 inhibitors. J Sex Med 2009; 6(3): 658-74.
[http://dx.doi.org/10.1111/j.1743-6109.2008.01107.x] [PMID: 19138362]
[167]
Frantzen J, Speel TG, Kiemeney LA, Meuleman EJ. Cardiovascular risk among men seeking help for erectile dysfunction. Ann Epidemiol 2006; 16(2): 85-90.
[http://dx.doi.org/10.1016/j.annepidem.2005.06.047] [PMID: 16226038]
[168]
Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol 2000; 36(1): 25-31.
[http://dx.doi.org/10.1016/S0735-1097(00)00705-1] [PMID: 10898408]
[170]
Patterson D, Kloner R, Effron M, et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol 2005; 60(5): 459-68.
[http://dx.doi.org/10.1111/j.1365-2125.2005.02479.x] [PMID: 16236035]
[171]
Kloner RA, Hutter AM, Emmick JT, Mitchell MI, Denne J, Jackson G. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol 2003; 42(10): 1855-60.
[http://dx.doi.org/10.1016/j.jacc.2003.09.023] [PMID: 14642699]
[172]
Emmick JT, Stuewe SR, Mitchel LM. Overview of the cardiovascular effects of tadalafil. Eur Heart J Suppl 2002; 4: 1132-47.
[http://dx.doi.org/10.1016/S1520-765X(02)90050-7]
[173]
Oliver JJ, Bell K, Leckie SM, et al. Interaction between glyceryl trinitrate and sildenafil citrate (Viagra) may last less than four hours. Int J Impot Res 2002; 14(Suppl. 3): 522.
[174]
La LR Presse Med 1949; 57: 906.
[175]
May AG, DeWeese JA, Rob CG. Changes in sexual function following operation on the abdominal aorta. Surgery 1969; 65(1): 41-7.
[PMID: 5762416]
[176]
Carstensen G. Treatment of impotentia coeundi by reconstructing the circulation in the internal iliac artery. Langenbecks Arch Chir 1969; 325: 885-8.
[http://dx.doi.org/10.1007/BF01256030] [PMID: 5372407]
[177]
Rogers JH, Karimi H, Kao J, et al. Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. Catheter Cardiovasc Interv 2010; 76(6): 882-7.
[http://dx.doi.org/10.1002/ccd.22646] [PMID: 20928837]
[178]
Michal V, Pospíchal J. Phalloarteriography in the diagnosis of erectile impotence. World J Surg 1978; 2(2): 239-48.
[http://dx.doi.org/10.1007/BF01553563] [PMID: 676335]
[179]
Herman A, Adar R, Rubinstein Z. Vascular lesions associated with impotence in diabetic and nondiabetic arterial occlusive disease. Diabetes 1978; 27(10): 975-81.
[http://dx.doi.org/10.2337/diab.27.10.975] [PMID: 700261]
[180]
Struyven J, Gregoir W, Giannakopoulos X, Wauters E. Selective pudendal arteriography. Eur Urol 1979; 5(4): 233-42.
[http://dx.doi.org/10.1159/000473119] [PMID: 436868]
[181]
Huguet JF, Clerissi J, Juhan C. Radiologic anatomy of pudendal artery. Eur J Radiol 1981; 1(4): 278-84.
[PMID: 7346273]
[182]
Buvat J, Lemaire A, Buvat-Herbaut M, Guieu JD, Bailleul JP, Fossati P. Comparative investigations in 26 impotent and 26 nonimpotent diabetic patients. J Urol 1985; 133(1): 34-8.
[http://dx.doi.org/10.1016/S0022-5347(17)48773-8] [PMID: 3155475]
[183]
Brühlmann W, Pouliadis G, Zollikofer C, Hauri D. Arteriography of the penis in secondary impotence. Urol Radiol 1982; 4(4): 243-9.
[http://dx.doi.org/10.1007/BF02924056] [PMID: 7168106]
[184]
Nessi R, De Flaviis L, Bellinzoni G, Freri F, Salvini A. Digital angiography of erectile failure. Br J Urol 1987; 59(6): 584-9.
[http://dx.doi.org/10.1111/j.1464-410X.1987.tb04882.x] [PMID: 3690189]
[185]
Gray RR, Keresteci AG, St Louis EL, et al. Investigation of impotence by internal pudendal angiography: experience with 73 cases. Radiology 1982; 144(4): 773-80.
[http://dx.doi.org/10.1148/radiology.144.4.7111723] [PMID: 7111723]
[186]
Valji K, Bookstein JJ. Transluminal angioplasty in the treatment of arteriogenic impotence. Cardiovasc Intervent Radiol 1988; 11(4): 245-52.
[http://dx.doi.org/10.1007/BF02577011] [PMID: 2975966]
[187]
Rosen MP, Greenfield AJ, Walker TG, et al. Arteriogenic impotence: findings in 195 impotent men examined with selective internal pudendal angiography. Young Investigator’s Award Radiology 1990; 174(3 Pt 2): 1043-8.
[http://dx.doi.org/10.1148/radiology.174.3.174-3-1043] [PMID: 2305087]
[188]
Rogers JH, Goldstein I, Kandzari DE, et al. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol 2012; 60(25): 2618-27.
[http://dx.doi.org/10.1016/j.jacc.2012.08.1016] [PMID: 23177300]
[189]
Gur S, Ozkan U, Onder H, Tekbas G, Oguzkurt L. The effect of endovascular revascularization of common iliac artery occlusions on erectile function. Cardiovasc Intervent Radiol 2013; 36(1): 84-9.
[http://dx.doi.org/10.1007/s00270-012-0359-3] [PMID: 22358994]
[190]
Wang TD, Lee WJ, Yang SC, et al. Safety and six-month durability of angioplasty for isolated penile artery stenoses in patients with erectile dysfunction: a first-in-man study. EuroIntervention 2014; 10(1): 147-56.
[http://dx.doi.org/10.4244/EIJV10I1A23] [PMID: 24832642]
[191]
Diehm N, Marggi S, Ueki Y, et al. Endovascular therapy for erectile dysfunction-who benefits most? Insights from a single-center experience. J Endovasc Ther 2019; 26(2): 181-90.
[http://dx.doi.org/10.1177/1526602819829903] [PMID: 30741067]
[192]
Wang TD, Lee WJ, Yang SC, et al. Clinical and imaging outcomes up to 1 year following balloon angioplasty for isolated penile artery stenosis in patients with erectile dysfunction: the PERFECT--2 study. J Endovasc Ther 2016; 23(6): 867-77.
[http://dx.doi.org/10.1177/1526602816669337] [PMID: 27629440]
[193]
Philip F, Shishehbor MH. Current state of endovascular treatment for vasculogenic erectile dysfunction. Curr Cardiol Rep 2013; 15(5): 360.
[http://dx.doi.org/10.1007/s11886-013-0360-8] [PMID: 23546827]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 3
Year: 2021
Published on: 13 April, 2020
Page: [301 - 312]
Pages: 12
DOI: 10.2174/1570161118666200414102556
Price: $65

Article Metrics

PDF: 37
HTML: 3